MedSurv: a software application for creating, conducting and managing medical surveys and questionnaires

MedSurv is a system designed for the rapid creation and maintenance of research surveys and questionnaires that does not require programmer intervention. MedSurv is built with medical surveys in mind and utilizes a group-based permission control with additional security features to help ensure compliance with applicable healthcare regulations. MedSurv is designed as a module for DotNetNuke [1], an open source portal and content management system built with ASP.Net technology, and therefore can be deployed and managed as intranet, extranet, and web sites. At the same time, all data is stored at the researcher\u27s institution to guarantee the required data privacy. Thanks to its built-in support for user authentication and user roles, there is no need to create such functionality from scratch. However, a group-based permissions system is added to MedSurv to support sufficient granularity for access control. Although from the data access point of view data storage acts as a relational table, MedSurv uses a solution that we call virtual tables. The premise behind such a solution is that the structure of the tables is itself stored in a set of relational tables within the database, essentially creating a miniature database within the database. This additional layer is transparent to the user and removes the need for any programming or database knowledge. At the same time it gives the user the flexibility of changing the survey at runtime. Unlike a traditional structure that may require database developer\u27s involvement each time a survey is added or changed, with virtual tables there is very low developer and database administration need after launch. MedSurv allows for creating complex medical surveys and is, in particular, used to develop questionnaires for research driven data collection in the Department of Gastroenterology

The Brain Tumor Segmentation (BraTS) Challenge 2023: Focus on Pediatrics (CBTN-CONNECT-DIPGR-ASNR-MICCAI BraTS-PEDs)

Pediatric tumors of the central nervous system are the most common cause of cancer-related death in children. The five-year survival rate for high-grade gliomas in children is less than 20\%. Due to their rarity, the diagnosis of these entities is often delayed, their treatment is mainly based on historic treatment concepts, and clinical trials require multi-institutional collaborations. The MICCAI Brain Tumor Segmentation (BraTS) Challenge is a landmark community benchmark event with a successful history of 12 years of resource creation for the segmentation and analysis of adult glioma. Here we present the CBTN-CONNECT-DIPGR-ASNR-MICCAI BraTS-PEDs 2023 challenge, which represents the first BraTS challenge focused on pediatric brain tumors with data acquired across multiple international consortia dedicated to pediatric neuro-oncology and clinical trials. The BraTS-PEDs 2023 challenge focuses on benchmarking the development of volumentric segmentation algorithms for pediatric brain glioma through standardized quantitative performance evaluation metrics utilized across the BraTS 2023 cluster of challenges. Models gaining knowledge from the BraTS-PEDs multi-parametric structural MRI (mpMRI) training data will be evaluated on separate validation and unseen test mpMRI dataof high-grade pediatric glioma. The CBTN-CONNECT-DIPGR-ASNR-MICCAI BraTS-PEDs 2023 challenge brings together clinicians and AI/imaging scientists to lead to faster development of automated segmentation techniques that could benefit clinical trials, and ultimately the care of children with brain tumors

Epidemiologic Investigation of Two Welder’s Anthrax Cases Caused by Bacillus cereus Group Bacteria: Occupational Link Established by Environmental Detection

Bacillus cereus group bacteria containing the anthrax toxin genes can cause fatal anthrax pneumonia in welders. Two welder’s anthrax cases identified in 2020 were investigated to determine the source of each patient’s exposure. Environmental sampling was performed at locations where each patient had recent exposure to soil and dust. Samples were tested for the anthrax toxin genes by real-time PCR, and culture was performed on positive samples to identify whether any environmental isolates matched the patient’s clinical isolate. A total of 185 environmental samples were collected in investigation A for patient A and 108 samples in investigation B for patient B. All samples from investigation B were real-time PCR-negative, but 14 (8%) samples from investigation A were positive, including 10 from patient A’s worksite and 4 from his work-related clothing and gear. An isolate genetically matching the one recovered from patient A was successfully cultured from a worksite soil sample. All welder’s anthrax cases should be investigated to determine the source of exposure, which may be linked to their worksite. Welding and metalworking employers should consider conducting a workplace hazard assessment and implementing controls to reduce the risk of occupationally associated illnesses including welder’s anthrax